Skip to content

4890.T

Tsubota Laboratory Incorporated

グロース · 医薬品 · 医薬品 · JP

JPY 300.00
+1.69%
Ask drillr

Year over year

Reported trailing growth

Revenue
-45.0%
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
-71.8%
EBITDA
EPS
-85.0%

Three-year CAGR

Revenue
+19.3%
EBITDA
+13.1%
EBIT
+18.6%
Net income
+50.9%
EPS
+48.2%
Free cash flow
-5.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026